Synthesis and pharmacological evaluation of m-terphenyl amines as cyclooxygenase inhibitors

Medicinal Chemistry Research

Volumn 16, Issue 3, 2007, Pages 119-129

  Bauer, John D ^a   Foster, Michael S ^b   Hugdahl, Jeffrey D ^c   Burns, Kristi L ^b   May, Sheldon W ^b   Pollock, Stanley H ^a   Cutler, Horace G ^a   Cutler, Stephen J ^d  

^a MERCER UNIVERSITY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c MERCER UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE INHIBITOR; TERPHENYL DERIVATIVE;

ARTICLE; BINDING SITE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

EID: 38949135176     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-007-9015-x     Document Type: Article

References (14)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343:1520-1528
2. Botting RM, Botting JH (2004) The discovery of COX-2. In: Pairet M, van Ryn J (eds) Milestones in Drug Therapy: COX-2 Inhibitors. Birkhaeuser, Switzerland, pp 1-13
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
4. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan CC (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74
5. Campaigne E, Bulbenko GF, Kreighbaum WE, Maulding DR (1962) Ring closure of ylidenemalononitriles. J Org Chem 27:4428-4432
6. Cutler SJ, Blanton CD, Akin DT, Steinberg FB, Moore AB, Lott JA, Price TC, May SW, Pollock SH (1998) The structure of human COX-2 and selective inhibitors. Inflamm Res 47:316-324
7. Degner F (2004) Efficacy and gastrointestinal safety of selective COX-2 inhibitors. In: Pairet M, van Ryn J (eds) Milestones in Drug Therapy: COX-2 Inhibitors. Birkhauser, Switzerland, pp 133-148
8. Kluepfel K, Horner L (1955) Zum nachweis des polaren Charakters in doppelbindungs-systemen phosphororganische Verbindungen II. Liebigs Ann Chem 591:69
9. Mowry DT (1945) The knoevenagel condensation of aryl alkyl ketones with malononitrile. J Am Chem Soc 67:1050-1051
10. Schiemenz GP (1962) Synthesen mit cyanessigsäure, III. zur reaktion von 2-hydroxy-benzaldehyd mit cyanacetamid und malodinitril. Chem Ber 95:483
11. Seibert K, Masferrer JL, Jiyi F, Hond A, Raz A, Needleman P (1990) The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukotriene Res 21:45-51
12. Sepiol J, Milan P (1985) A new and efficient synthesis of 3,5-diarylaminobenzenes from arylidenemalonodinitriles and 1- atylethylidenemalonodinitriles. Tetrahedron 41:5261-5265
13. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232-235
14. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568